Janahan Ph.D.

Staff Engineer, R&D at ViaCyte - San Diego, CA, US

Janahan Ph.D.'s Colleagues at ViaCyte
Jonathan Smith

Process Sustaining Engineer

Contact Jonathan Smith

Isobelle Espiritu

Engineer I, Process Development

Contact Isobelle Espiritu

Carl Gunn

Materials Management Associate

Contact Carl Gunn

Alyssa Levin

Chief Financial Officer

Contact Alyssa Levin

Steven Kradjian

VP Regulatory & Quality Officer

Contact Steven Kradjian

Shannon Ortiz

Senior Accounts Payable Specialist

Contact Shannon Ortiz

View All Janahan Ph.D.'s Colleagues
Janahan Ph.D.'s Contact Details
HQ
858-207-0500
Location
Company
ViaCyte
Janahan Ph.D.'s Company Details
ViaCyte logo, ViaCyte contact details

ViaCyte

San Diego, CA, US • 100 - 249 Employees
BioTech/Drugs

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.About ViaCyte's Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

B2B Biotechnology Healthcare Pharmaceuticals Biotech BioTech/Drugs Commercial Physical Research
Details about ViaCyte
Frequently Asked Questions about Janahan Ph.D.
Janahan Ph.D. currently works for ViaCyte.
Janahan Ph.D.'s role at ViaCyte is Staff Engineer, R&D.
Janahan Ph.D.'s email address is ***@viacyte.com. To view Janahan Ph.D.'s full email address, please signup to ConnectPlex.
Janahan Ph.D. works in the Biotechnology industry.
Janahan Ph.D.'s colleagues at ViaCyte are Jonathan Smith, Isobelle Espiritu, Andres Aguirre, Carl Gunn, Alyssa Levin, Steven Kradjian, Shannon Ortiz and others.
Janahan Ph.D.'s phone number is null
See more information about Janahan Ph.D.